文献速递前列腺癌

转移性去势抵抗性前列腺癌患者接受卡巴他赛治疗的真实世界证据:与随机临床研究CARD的比较

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-17

该回顾性全球肿瘤数据库研究比较了真实世界中类CARD队列与CARD随机试验患者的特征和治疗模式。类CARD队列患者疾病特征更 unfavorable,更多患者接受过≥2线ARTA,但卡巴他赛治疗持续时间相似(21.9 vs 22.0周)。结果提示CARD人群可反映常规临床实践。

要点

  • 真实世界中35.1%患者接受≥2线ARTA,42%一线ARTA后二线再用ARTA。
  • 类CARD队列ECOG PS≥2者占45%,远高于CARD的4.7%。
  • 尽管更多患者用卡巴他赛20 mg/m2(55% vs 21%),治疗持续时间相似。

核心结论

  • ARTA序贯使用频繁;结果提示CARD人群可反映常规临床实践,真实世界人群中卡巴他赛的缓解持续时间相似。

研究设计与样本

  • 回顾性、全球肿瘤数据库(Medimix Live TrackerTM)分析,收集2001-2019年欧洲、美国、巴西和日本医疗专业人员报告的电子患者医疗表格。
  • 数据库包含12,140例接受≥1线治疗的mCRPC患者;类CARD队列纳入接受过多西他赛、既往阿比特龙/恩扎卢胺和卡巴他赛治疗的患者452例。

主要发现

  • 35.1%患者接受≥2线ARTA;接受一线ARTA的患者中42%在二线接受另一种ARTA。
  • 类CARD队列中位年龄73岁 vs CARD 70岁;ECOG PS≥2者45% vs 4.7%;诊断时转移46% vs 38%;Gleason 8-10分65% vs 57%。
  • 类CARD队列更多患者在多西他赛前接受ARTA(48% vs 39%)且首次ARTA治疗>12个月(30% vs 17%)。
  • 类CARD队列更多患者接受卡巴他赛20 mg/m2较低剂量(55% vs 21%),但卡巴他赛治疗持续时间相似(21.9 vs 22.0周)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative androgen-receptor-targeted agent (ARTA). The objective was to compare characteristics and treatment patterns of patients from a real-world dataset with the CARD population. METHODS: Real-world data were collected from Medimix Live TrackerTM, a retrospective, global oncology database of healthcare professional-reported electronic patient medical forms (2001-2019), with data from patients from Europe, USA, Brazil and Japan. The database contained patient, tumor and treatment information for 12,140 patients who received ≥1 line of treatment for mCRPC. A CARD-like cohort included patients treated with docetaxel, prior abiraterone/enzalutamide and cabazitaxel. RESULTS: A large proportion of patients received ≥2 lines of ARTA (35.1%) with 42% of patients who received a first-line ARTA receiving another ARTA in second line. Of the total patients, 452 were eligible for the CARD-like cohort. Median age of the CARD-like cohort was comparable to CARD (73 vs 70 years). The CARD-like cohort had unfavorable disease characteristics vs CARD: ECOG PS ≥ 2 (45% vs 4.7%); metastasis at diagnosis (46% vs 38%) and Gleason 8-10 (65% vs 57%). More patients in the CARD-like cohort received ARTA before docetaxel (48% vs 39%) and received the first ARTA for >12 months (30% vs 17%) compared with CARD. Despite more patients in the CARD-like cohort receiving the lower 20 mg/m2 dose of cabazitaxel (55% vs 21%), cabazitaxel treatment duration was similar (21.9 vs 22.0 weeks). CONCLUSIONS: Sequential use of ARTA was frequent. Results indicate the CARD population is reflective of routine clinical practice and duration of response to cabazitaxel was similar in a real-world population.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. de Wit R, Freedland SJ, Oudard S, et al. Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. Prostate Cancer Prostatic Dis. 2022. PMID: 35039605. doi:10.1038/s41391-021-00487-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。